GSK Acquires RAPT Therapeutics for $2.2 Billion to Develop New Food Allergy Treatment
GSK purchases RAPT Therapeutics for $2.2B, gaining ozureprubart - a promising food allergy treatment requiring injections every 12 weeks instead of every 2 weeks.
/ 1660 items
#XY↓
Genmab's Epcoritamab Trial Falls Short on Key Survival Metric
Genmab's Phase 3 trial for epcoritamab shows mixed results in lymphoma patients, missing its overall survival goal despite some improvements.
Novo Nordisk's Wegovy Weight-Loss Pill Shows Promising Early Sales Data
Novo Nordisk's new Wegovy weight-loss pill records over 3,000 prescriptions in its first four days, signaling strong market entry as competition with Eli Lilly intensifies in the booming obesity treatment sector.
Arbutus Loses Key European Patent in Moderna Dispute
Arbutus Biopharma shares dropped 16% after losing European patent dispute with Moderna. The biotech plans to appeal the ruling that affects ongoing litigation.
Goldman Sachs Upgrades BioNTech to Buy, Sees Strong Cancer Therapy Potential
Goldman Sachs raises BioNTech to Buy, citing its strong position in oncology and upcoming 2026 data that could boost new cancer therapies.
FDA Grants Orphan Drug Status to (Z)-Endoxifen for Duchenne Muscular Dystrophy
Atossa Therapeutics receives FDA orphan drug designation for (Z)-endoxifen to treat Duchenne muscular dystrophy, a rare genetic muscle-wasting disease.